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Background: Various trials have been conducted on the management and treatment of androgenic alopecia (AGA)
or male pattern hair loss using a variety of laser and light sources.
Methods: For this feasibility study, the population was composed of males between the ages of 20 and 60 years
who have been experiencing active hair loss within the last 12 months and the diagnosis of AGA. They also had a
Norwood-Hamilton classification of 3, 3A, 3 V, 4, 4A, or 5 for the hair thinning patterns and skin type I, II, III, or IV on
the Fitzpatrick skin type scale. This two-arm randomized, parallel group study design employed stratifying
randomization to balance treatment assignment within three investigational centers with at least 2 subjects enrolled
in each Fitzpatrick skin type.
Results: A statistically significant positive trend in hair growth was observed from this pilot study, to evaluate the
efficacy of the novel cold X5 hairlaser device for treating male androgenic alopecia. From the repeated measures
analysis of variance, difference in mean hair counts over time was statistically significant (F = 7.70; p-value < 0.0001).
Subsequent, linear regression of mean hair counts at each time point was performed, and post-hoc analysis found
an increasing trend of hair growth over time that was statistically significant (p-value < 0.0001) with the estimated
slope of 1.406. Increased hair counts from the baseline to the end of the 26-week period were found to be strongly
significant (p-value = 0.0003).
Conclusion: Albeit, sham device failure and resultant missing data from the control group, the positive trend hair
growth, was observed due to the chronic use of X5hairlaser device. This positive benefit while in full agreement
with other low laser hair devices requires intensive further investigation.
Trial registration: NCT02067260
Keywords: Androgenic alopecia, Distributed laser light, Monochromatic light, Linear regressionBackground
Epidemiology: defining androgenic alopecia
Androgenic alopecia (also known as androgenetic alopecia
or alopecia androgenetica) is the most common cause of
hair loss, and thinning in humans [1]. Androgenic alopecia
(AGA) affects an estimated 50 million men and 30 million
women in the United States. Genetic predisposition to
hereditary hair loss can be inherited from either side of a* Correspondence: drd2gene@gmail.com
1Department of Psychiatry and McKnight Brain Institute, University of Florida,
College of Medicine, Gainesville, FL, USA
3Department of Nutrigenomics, IGENE, LLC, Austin, TX, USA
Full list of author information is available at the end of the article
© 2014 Blum et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orperson’s family or both parents. It is found in men and
women of all races and ethnicities. By age 40, forty percent
of women and nearly forty percent of men have visible
symptoms of hereditary hair loss. By age 50, fifty percent
of both genders show signs of the condition. Hair loss
is a common and distressing condition. Americans are
expected to spend about one billion dollars annually for
treatments to combat and cover up hair loss [2,3].
It is well known that both Finasteride® and Minoxidil®
are effective treatment methods, but patients who exhibit
a poor response to these methods have no additional
adequate treatment modalities [4,5]. In this regard,
Kim et al. reported that after 24 weeks of treatment, atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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greater hair density than the sham device group [6]. In
addition Leavitt et al. [7] reported that the HairMax
LaserComb treatment group showed a significantly greater
increase in mean terminal hair density than subjects in the
sham device group (p < 0.0001). Moreover, significant
improvements in overall hair regrowth were demonstrated
in terms of patients' subjective assessment (p < 0.015) at
26 weeks when compared to baseline.
Variants appear in both men and women. However,
AGA is also commonly known as male pattern baldness.
In males’ classic pattern baldness, hair is lost in a well-
defined pattern, beginning above both temples. Hair also
thins at the crown of the head. Often a rim of hair
around the sides and rear of the head is left. This pattern
is dubbed "Hippocratic balding" and may rarely progress
to complete baldness. Women do not suffer classic male
pattern baldness, instead the hair becomes thinner around
the whole scalp, and the hairline does not recede. This
is dubbed "female pattern baldness" and may occur in
males. This variety of AGA in women rarely leads to
total baldness [1,8].
Androgenic alopecia
More than 95 percent of hair loss in men is caused by
AGA. Male pattern baldness is considered a genetic
condition, inherited from either the mother or the
father's side of the family. However, male pattern baldness
also requires the presence of the male hormone testoster-
one. Genetics cause hair follicles to become sensitive to di-
hydrotestosterone (DHT), a byproduct of testosterone [9].
The follicles begin to grow smaller, have a shorter life span
and eventually fall out altogether or leave behind fuzz.
Various genetic (and possibly environmental-epigenetic)
factors apparently play a role in AGA. Although re-
searchers have long studied the factors that may con-
tribute to this condition, many remain unknown.
Recently the existing theories have been challenged on
the ground that while the androgens in question are
responsible for hair growth on the face and all over the
body of men, hair loss only occurs at the top of the
scalp. For example, it has been suggested that AGA is a
consequence of the anabolic effect of androgens such as
hormonal changes leading to structural changes in skin
and scalp which in turn cause hair loss [10]. It should be
noted, however, that there are as of yet no experiments
testing this hypothesis.
The genetic and hormonal component of male
pattern baldness
Much research concerns the genetic component of male
pattern baldness, or AGA research indicates that sus-
ceptibility to premature male pattern baldness is largely
X –linked, which means it is linked to genes on anX-chromosome. Other genes that are not sex linked are
also involved. Men whose fathers had experienced hair
loss, were 2.5 times more likely to experience hair loss
themselves, regardless of the mother's side of the family
[11,12]. Large studies in 2005 and 2007 stress the im-
portance of the maternal line in the inheritance of male
pattern baldness. German researchers name the andro-
gen receptor gene as a necessary condition for balding
[11]. They concluded that a specific variant of the an-
drogen receptor is needed for AGA to develop. This
study has been confirmed by other researchers [13].
The androgen receptor gene is recessive. Thus, a female
would need two X chromosomes with the defect to
show typical male pattern alopecia. Since androgens
and their interaction with the androgen receptor are
the cause of AGA, the androgen receptor gene plays an
important part in its development. There is a plethora of
research concerning the role of genes and hormones in the
development of male androgenic alopecia and reviewed
elsewhere [14-22]. Studies on hormonal imbalance have
also been well documented in the literature including
concepts involving inhibition of 5-alpha- reductase [23].
Description of X5 hairlaser
The X5 HairLaser delivers distributed laser light to the
scalp for stimulating hair growth in men diagnosed with
AGA. The X5 HairLaser is a precision instrument utiliz-
ing cold beam low-level laser light. The X5 HairLaser
provides 15 distinct points of laser light to cover an area
over nine square inches (23 cm.) of the scalp. Separately
molded high quality lenses allow the laser beams to be
directed at the scalp directly. The X5 HairLaser provides
direct scalp contact since the laser light is delivered by
proprietary laser channels, which make direct contact
with the scalp. The laser light is not obstructed by exist-
ing hair. The X5 HairLaser contains a floating mem-
brane system that insures that light channels conform to
the shape of the head and scalp. The X5 HairLaser is a
cordless device that contains a rechargeable battery in
its base. One charge will supply cordless power for
several treatments.
The X5 HairLaser has fifteen lasers diodes and fifteen
beam-focusing tines. Each tine houses its own laser
diode. The fifteen tines are arranged into five groups of
three. Each group of three tines moves independently
providing perpendicular laser delivery to the user’s scalp.
The beam focusing lenses are integrally attached to
tines, the tines align the lasers, directly (axially) with the
lens. The beam is projected towards the user’s scalp. The
tines through which the laser beam is delivered, also part
the user’s hair to deliver the laser beam directly to the
scalp without obstruction (see Figure 1).
The X5 HairLaser incorporates a colored LCD display
that displays the precise elapsed time of the treatment
Figure 1 X5 HairLaser.
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charging status of the unit. The X5 HairLaser device is
operated by; turning it on, holding the device against the
scalp for approximately 15 seconds, then moving it
slightly, to a different position on the head. The device is
repositioned every 15 seconds in a clockwise or counter-
clockwise direction. After 10–15 minutes, the session is
complete once all of the target areas of the scalp have
been given significant exposure to low-level laser light.
Hypothesis
Based on the literature to date we decided to systemat-
ically test the “Cold” X5 Hairlaser™ as a laser device
known to deliver distributed laser light to the scalp for
stimulating hair growth in men diagnosed with AGA.
Methods
Study design
This feasibility study was designed to evaluate the effi-
cacy of the X5 HairLaser, a hand-held, low-level laser
device, for the stimulation of hair growth. This study of
the X5 HairLaser intended to increase terminal hair
growth in males with AGA, was a multi-center, random-
ized, placebo-controlled study conducted at three sites in
the United States. The trial was provided a clinical proto-
col number by ClinicalTrials.gov Protocol Registration
System number NCTO2O67260.
Subjects
In this pilot study we relied on the American Academy
of Dermatology for hair loss guidelines as part of the in-
clusion criteria for enrolled patients [24]. The participantswho met all entry criteria were randomized in a 2:1 fash-
ion to receive treatment with either the X5 HairLaser or
an identical sham device that does not emit laser light.
The study population was composed of males between the
ages of 20 and 60 years with diagnosis of AGA who
had been experiencing active hair loss within the past
12 months. They were also required to have a Norwood-
Hamilton classification of 3, 3A, 3 V, 4, 4A, or 5 for the
hair thinning patterns and have the skin type I, II, III, or
IV on the Fitzpatrick skin type scale (see Inclusion and
Exclusion Criteria below). The study was approved by
Institution Review Boards (IRB) of the three selected
sites. Each subject filled out an approved consent form.
Specifically, the IRB was Biomedical Research Alliance
of New York (BRANY), 1981 Marcus Avenue Suite 210,
Lake Success, New York 11042 (file number 08-02-31-161).
The three research locations are listed below the IRB
covered all of them: 1) NYU School of Medicine 560 First
Avenue, Room 158 New York, NY 10016; (2) Burke
Pharmaceutical Research 3633 Central Avenue Suite I,
Hot Springs, AR 71913; (3) Hilltop Research 6699
13th Avenue N, St. Petersburg, FL 33710.
Inclusion criteria
 Male with Androgenic Alopecia.
 Active hair loss within the last 12 months.
 Good general health.
 Norwood-Hamilton classification of 3, 3A, 3V, 4,
4A or 5.
 Skin Type I, II, III, or IV on the Fitzpatrick Skin
Type Scale.
 Has not started any new vitamins or nutritional
supplements.
 Continued normal grooming habits.
 Adhering to scheduled office visits in a
timely manner.
 Diagnosed according to Guidelines of the American
Academy of Dermatology Association.
 Subject must have miniaturized hair present in the
target area.
 Subject must be fluent in English.
 Signed an informed consent.
Exclusion criteria
 Active malignancy of any type or history of any
malignancy, including any malignancy in the
treatment area in the past five years.
 History of hypogonadism.
 Subject has used phytotherapy (e.g., saw palmetto)
within eight weeks prior to baseline.
 Any active skin infection in the scalp area or
scarring in the target area.
Table 1 Frequency distribution of the Norwood Hamilton
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 Has used Accutane® in the previous year.
 History of poor wound healing.
 History of anticoagulant or antiplatelet use
(other than aspirin ≤325 mg., QD, which is stable
for three months.
 Has "buzz" cut hairstyle, defined as hair cut to less
than one inch in length.
 Has light blond, light gray or white hair.
 Has a chronic dermatological condition
(eczema, psoriasis, infection, etc.) of the scalp.
 Has a pacemaker.
 Has had hair transplants, scalp reduction, current
hair weave, or tattooing in the target area.
 Has ever received radiation therapy to the scalp, or
has had chemotherapy within the past year.
 Has HIV infection, connective tissue disease, a
thyroid condition, inflammatory bowel disease.
 Has a history or evidence of drug and/or
alcohol abuse within the 12 months prior to
Visit 1.
 History or the presence of any serious and/or
chronic medical condition(s) [including psychiatric
illnesses.
 Has used or currently takes Minoxidil (Rogaine™)
during twelve months prior to screening.
 Has taken any of the following medications during
the six months prior to screening:
◦ finasteride, (or any other 5á–reductase
inhibitor medications),
◦ medications with anti-androgenic properties
(e.g., cyproterone acetate, spironolactone,
ketoconazole, flutamide, bicalutamide),
◦ topical estrogen, progesterone, tamoxifen,
anabolic steroids,
◦ medications which can potentially cause
hypertrichosis (e.g., cyclosporine, diazoxide,
phenytoin, psoralens),
◦ oral glucocorticoids (inhaled glucocorticoids are
permitted), lithium, phenothiazines.ble 2 Sample statistics of the hair counts from the complet
Sample statistics Baseline Week 4
Minimum 22.0 37.0
25% Percentile 130.8 144.0
Median 168.0 181.0
75% Percentile 204.5 210.0
Maximum 297.0 302.0
Mean 163.80 174.70
Standard deviation 65.60 61.87
Standard error 9.47 8.93
% Confidence interval (144.8, 182.9) (156.7, 192.6) (1Design and subject demographics
A two-arm randomized, parallel group design was
employed for this study, stratifying the randomization
to balance treatment assignment within 3 investigational
centers. Additionally, in the sampling scheme, at least 2
subjects were required to be enrolled in each Fitzpatrick
skin type.
A total of 143 study participants were screened on
their first visit, based on the inclusion/exclusion criteria
and 119 subjects (83.22%) were entered into the study.
The diagnosis of male Androgenic Alopecia was made
by a trained medical Dermatologist utilizing in many
cases modern hair imaging techniques including trichos-
can and or trichoscopy.
They were almost uniformly distributed, resulting in
approximately 40 subjects enrolled at each of the 3 dif-
ferent study sites. Of those 119 subjects, 70 of them
(58.82%) were treated with the X5 hairlaser device while
others (41.18%) received the placebo. The study con-
sisted of 5 follow-up visits for the period of 26 weeks.
On each visit of the subject, some clinical measurements
were taken along with the hair count data which was
provided by the imaging vendor, Canfield.
The primary objective of the study was to prove the ef-
ficacy and safety of the X5 hairlaser device for treating
male AGA through comparison to the control. However,
due to a problem in the implementation of the proposede data (n = 48)
Week 8 Week 14 Week 20 Week 26
31.0 21.0 26.0 11.0
137.0 155.3 144.0 136.5
168.5 184.5 176.5 183.0
217.0 227.5 216.3 229.5
329.0 335.0 311.0 321.0
173.80 185.20 176.20 180.30
71.32 69.90 68.43 73.05
10.29 10.09 9.88 10.54
53.1, 194.5) (164.9, 205.5) (156.3, 196.1) (159.1, 201.5)
Figure 2 Box-and-whisker plots of the hair counts from the complete data (n = 48).
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the sham device unbeknown to us constituted a laser
type lighting effect. This light affected subsequent ana-
lysis on this report. While we are cognizant of the
impact of the loss of sham control data we decided to
conduct pilot data from the treatment group only, ex-
cluding the data from the control placebo group. Hence,
the focus of this report is to investigate the presence of
positive hair growth in the treatment group by examin-
ing the trend in hair counts of the 70 treated subjects
(viz., a sample of the Intent-to-Treat (ITT) population).
For each subject in this study, the hair counts were
supposed to be taken at 6 different time points: Baseline,
Week 4, Week 8, Week 14, Week 20, and Week 26.
Twenty-two subjects (31.4%) from the treatment group
are however missing at least one such measurement
from the given dataset due to loss to follow-up or with-
drawal from the study, etc. Since it is crucial to have a
complete dataset for running a repeated measures ana-
lysis of variance (ANOVA) and to test any linear trendFigure 3 Box-and-whisker plots of the hair counts from the complet
measurement group).over time, data from 48 subjects who completed all
study visits with 6 valid hair count measurements were
analyzed first in order to confirm any positive trend in
the hair growth over time (i.e., a per-protocol analysis).
Then, the missing hair counts of 22 remaining subjects
with the baseline and at least one valid post-baseline
assessment were imputed by carrying the most recent
observation from the previous visits to the missing one
(s) for each subject (viz., the method of last observation
carried forward (LOCF)). The analysis was conducted
again on the dataset of all 70 subjects, mixed with the
imputed observations.
The brief demographic characteristics of the treatment
group are as follows. The age distribution was found to
be 47.60 ± 7.82 (mean ± SD) for the partial group of 48
subjects with complete hair counts and 47.04 ± 8.55 for
the group of all 70 subjects. There were 7 Hispanic or
Latino participants (10.0%) while other 63 (90.0%) were
neither Hispanic nor Latino. The race was all white ex-
cept for one African American and one native Hawaiiane data (n = 48). (Empty dots indicate the outliers from each
Table 3 Sample statistics of the hair counts from the mixed data (n = 70)
Sample statistics Baseline Week 4 Week 8 Week 14 Week 20 Week 26
Minimum 22.0 33.0 22.0 21.0 26.0 11.0
25% Percentile 121.0 125.3 130.8 137.3 135.3 129.5
Median 164.0 172.0 165.0 182.5 172.0 181.5
75% Percentile 201.5 203.5 214.8 224.5 214.3 225.3
Maximum 303.0 302.0 329.0 335.0 311.0 321.0
Mean 159.00 167.90 169.30 178.90 170.00 174.80
Standard deviation 65.39 63.55 71.24 69.63 67.46 68.97
Standard error 7.82 7.60 8.52 8.32 8.06 8.24
95% Confidence interval (143.4, 174.6) (152.7, 183.1) (152.4, 186.3) (162.3, 195.5) (153.9, 186.1) (158.4, 191.2)
Table 4 Sample statistics of the hair counts from 3 age groups of the complete data (n = 48)
Sample statistics Baseline Week 4 Week 8 Week 14 Week 20 Week 26
(a) Age group: Young (40 or below) (n = 10)
Minimum 26.0 89.0 33.0 63.0 74.0 64.0
25% Percentile 119.8 137.8 105.0 114.8 87.8 85.5
Median 191.0 198.0 220.5 224.0 202.0 227.0
75% Percentile 224.8 249.3 261.0 264.8 257.8 239.5
Maximum 280.0 279.0 286.0 292.0 311.0 321.0
Mean 170.40 193.60 188.30 203.90 187.00 192.60
Standard deviation 81.78 62.11 87.63 79.59 83.69 85.27
Standard error 25.86 19.64 27.71 25.17 26.46 26.96
95% Confidence Interval (111.9, 228.9) (149.2, 238.0) (125.6, 251.0) (147.0, 260.8) (127.1, 246.9) (131.6, 253.6)
(b) Age group: Mid (between 41 and 50 inclusive) (n = 19)
Minimum 43.0 51.0 42.0 38.0 26.0 11.0
25% Percentile 138.0 155.0 152.0 159.0 157.0 147.0
Median 165.0 182.0 166.0 186.0 178.0 180.0
75% Percentile 194.0 207.0 208.0 219.0 204.0 228.0
Maximum 269.0 262.0 272.0 259.0 265.0 264.0
Mean 161.60 171.90 170.30 183.30 174.60 178.70
Standard deviation 54.98 53.10 56.82 55.01 58.58 62.84
Standard error 12.61 12.18 13.03 12.62 13.44 14.42
95% Confidence interval (135.1, 188.1) (146.4, 197.5) (142.9, 197.7) (156.7, 209.8) (146.3, 202.8) (148.5, 209.0)
(c) Age group: Old (between 51 to 60 inclusive) (n = 19)
Minimum 22.0 37.0 31.0 21.0 31.0 29.0
25% Percentile 109.0 114.0 110.0 126.0 133.0 114.0
Median 169.0 164.0 159.0 175.0 168.0 157.0
75% Percentile 203.0 203.0 206.0 196.0 203.0 206.0
Maximum 297.0 302.0 329.0 335.0 308.0 320.0
Mean 162.50 167.40 169.60 177.20 172.20 175.40
Standard deviation 69.56 70.61 77.89 79.36 72.17 78.97
Standard error 15.96 16.20 17.87 18.21 16.56 18.12
95% Confidence interval (129.0, 196.1) (133.4, 201.5) (132.0, 207.1) (139.0, 215.5) (137.4, 206.9) (137.3, 213.4)
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Figure 4 Mean profile plots of the hair counts from 3 age groups of the complete data (n = 48).
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Norwood Hamilton classification of the treated subjects
is also shown in the Table 1 below.
We did not systematically rule out other overlapping
causes of hair loss but we were confident that the sub-
jects tested had a well-documented diagnosis of male
androgenic alopecia.Results
Overall trend of hair growth
With an appropriate aggregation of the classes, none
of the variables aforementioned including the distribu-
tion of the Fitzpatrick skin type classification and the
grouped age variable was found to have a statistically
significant association with one another at 5% level
of significance.
Table 2 below summarizes the essential sample statis-
tics from the hair counts of 48 subjects with complete
observations at each measurement point over the period
of 26 weeks. The mean profile was plotted to visualize
the results, and it is shown in Figure 2 below, assuming
that the measurements were taken in an approximately







Complete data (n = 48) Young 10 1.65
Mid 19 3.76
Old 19 3.24
Mixed data (n = 70) Young 15 2.66
Mid 29 5.12
Old 26 5.38From Figure 2, an overall increasing-trend is apparent.
The amount of variability is also increasing at each
measurement point (as shown in the comparative box-
and-whisker plots of Figure 3 above). From the repeated
measures analysis of variance, it was shown that the
difference in mean hair counts over time is statistically
significant (F = 7.70; p-value < 0.0001). Subsequently, a
linear regression on the mean hair counts at each meas-
urement time point was performed as a post-hoc ana-
lysis, and it was found that a systematically increasing
trend of hair growth over time is statistically significant
(p-value < 0.0001) with the estimated slope of 1.406.
However, the R2 value of 0.0050 indicated the presence
of a large amount of variability which cannot be ex-
plained by the duration of the device usage only. For this
reason, it was not successful to model the trend in the
hair counts over time using a growth curve approach.
When the end points alone were considered, an increase
in the hair counts from the baseline to the end of the
26-week period was nevertheless found to be strongly
significant (p-value = 0.0003).
Consistent results were obtained using the mixed data-
set of 70 subjects with some imputed values. Table 3
summarizes the sample statistics calculated from thisach age group
d measures ANOVA Post-hoc linear trend test
p-value p-value Slope R2 value
0.1663 – – –
0.0039 0.0013 1.520 0.0086
0.0098 0.0009 1.229 0.0033
0.0295 0.1054 1.215 0.0036
0.0002 0.0004 1.337 0.0066
0.0002 < 0.0001 1.455 0.0046
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over the period of 26 weeks. Again from the repeated
measures analysis of variance, the change in mean hair
counts over time was shown to be statistically significant
(F = 10.60; p-value < 0.0001). From the post-hoc analysis,
a linear regression on the mean hair counts at each
measurement time point revealed the statistically signifi-
cant presence of a linearly-increasing trend of the hair
growth over time (p-value < 0.0001) with the slightly
smaller slope estimate of 1.355. Again, a very low R2
value of 0.0047 indicated the presence of a large amount
of variability.
Trend of hair growth by Age group
In order to examine any differential effect of the device
on the hair growth trend of different age groups, the
treated subjects were grouped into 3 different classes: (a)
Young (40 or below), (b) Mid (between 41 to 50 inclu-
sive), and (c) Old (between 51 to 60 inclusive). The 3
classes were chosen such that each holds an approxi-
mately uniform number of observations from the data-
set. Table 4 below provides the sample statistics of the
hair counts from each of these age groups formed from
the dataset of 48 subjects with complete observations.
Figure 4 describes the mean profile plots of the hair
counts of these age groups over the period of 26 weeks.
From Figure 3, a similar overall increasing pattern is
observed among the 3 age groups. Although the Young
group had higher average hair counts at the baseline
compared to the Mid or Old groups, the increments of
hair counts by the end of the 26-week period were quite
comparable among all 3 groups. All three age groups
shared remarkably similar mean profiles, but the patternFigure 5 Mean profile plots of the hair counts from 4 Fitzpatrick skinof the Young group, was observed to be more erratic,
with a larger variation, while the Mid and Old groups
exhibited similar and consistent trends of increasing hair
counts over time.
Table 5 below summarizes the results of formal statis-
tical tests to detect the mean difference of hair counts
across the measurement time points by the repeated
measures analysis of variance. The tests were performed
for each of the 3 age groups, and once the results were
found to be significant, the post-hoc analysis of a linear
trend over time was conducted.
Between the complete dataset of 48 subjects and the
mixed dataset of 70 subjects, the results of analysis
were largely consistent. Although the imputation helped
to capture the marginal significance of the mean dif-
ference of hair counts over time for the Young group
(p-value = 0.0295), a linear trend of the hair growth was
still not detected (p-value = 0.1054) from the post-hoc
analysis as in the complete data case. This may be due
to a smaller sample size allocated for the group Young,
resulting in higher variability and a more erratic profile
as shown in Figure 3. Although the graphical trends are
similar across the groups, it seems that the older groups
exhibit slightly more consistent and stronger linear trend
of the hair growth over time Figure 5. As pointed out
earlier though, low R2 values indicated the presence of
a large amount of variability which cannot be explained
by the duration of the device usage only.
Trend of hair growth by skin type
To determine the presence, of any effect of the device
on the hair growth trends that was dependent on skin-
type, the subjects were divided into 4 groups accordingtypes of the complete data (n = 48).
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and IV being the least sensitive). Each class held an
approximately uniform number of observations from the
dataset. Table 6 below summarizes the sample statisticsTable 6 Sample statistics of the hair counts from 4 Fitzpatrick
Sample statistics Baseline Week 4
(a) Fitzpatrick skin type I (n = 6)
Minimum 22.0 37.0
25% Percentile 37.8 51.3
Median 119.0 119.0
75% Percentile 197.0 213.8
Maximum 227.0 279.0
Mean 119.50 133.70
Standard deviation 83.47 94.21
Standard error 34.08 38.46
95% Confidence interval (31.9, 207.1) (34.8, 232.5) (
(b) Fitzpatrick skin type II (n = 13)
Minimum 26.0 89.0
25% Percentile 104.5 116.5
Median 150.0 180.0
75% Percentile 192.0 196.0
Maximum 297.0 302.0
Mean 150.30 166.50
Standard deviation 72.79 56.90
Standard error 20.19 15.78
95% Confidence interval (106.3, 194.3) (132.2, 200.9) (1
(c) Fitzpatrick skin type III (n = 15)
Minimum 48.0 51.0
25% Percentile 138.0 144.0
Median 166.0 167.0
75% Percentile 214.0 211.0
Maximum 280.0 274.0
Mean 167.70 172.00
Standard deviation 62.89 59.82
Standard error 16.24 15.45
95% Confidence interval (132.8, 202.5) (138.9, 205.1) (1
(d) Fitzpatrick skin type IV (n = 14)
Minimum 128.0 142.0
25% Percentile 163.0 160.0
Median 185.5 197.0
75% Percentile 225.8 244.8
Maximum 269.0 268.0
Mean 191.20 202.60
Standard deviation 42.61 43.48
Standard error 11.39 11.62
95% Confidence interval (166.6, 215.8) (177.5, 227.7) (1of the hair counts in each of these skin types from the
complete dataset of 48 subjects. Figure 5 shows the
mean profile plots of the hair counts of these 4 skin
types over the period of 26 weeks. The more sensitiveskin types of the complete data (n = 48)
Week 8 Week 14 Week 20 Week 26
31.0 21.0 26.0 11.0
46.0 33.8 29.8 24.5
131.0 124.5 133.5 139.5
199.8 217.0 203.8 242.3
256.0 250.0 269.0 264.0
130.20 127.30 129.20 136.30
87.43 94.15 96.38 107.30
35.69 38.44 39.35 43.82
38.4, 221.9) (28.5, 226.1) (28.0, 230.3) (23.7, 249.0)
33.0 63.0 74.0 64.0
101.5 120.0 121.0 109.0
156.0 185.0 157.0 163.0
185.5 223.0 200.5 213.5
329.0 335.0 308.0 313.0
155.20 179.60 166.70 164.90
71.08 70.25 62.89 69.72
19.71 19.49 17.44 19.34
12.2, 198.1) (137.2, 222.1) (128.7, 204.7) (122.8, 207.1)
42.0 77.0 52.0 75.0
137.0 149.0 143.0 133.0
166.0 177.0 168.0 163.0
217.0 226.0 224.0 226.0
309.0 314.0 304.0 320.0
172.20 182.10 173.40 177.80
67.89 64.64 67.00 71.35
17.53 16.69 17.30 18.42
34.6, 209.8) (146.3, 217.9) (136.3, 210.5) (138.3, 217.3)
130.0 156.0 140.0 153.0
155.5 179.5 171.5 179.3
211.5 200.0 196.0 211.0
269.0 265.5 256.0 244.8
286.0 292.0 311.0 321.0
211.40 218.40 208.20 216.10
55.40 49.19 51.44 48.74
14.81 13.15 13.75 13.03
79.4, 243.4) (190.0, 246.8) (178.5, 237.9) (187.9, 244.2)
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baseline from Figure 5. It was also interesting to observe
that among the 4 skin types, the type IV exhibits the
strongest pattern of hair counts increasing linearly over
time, and this was statistically confirmed by the test
results shown in Table 7.
Table 7 above summarizes the results of statistical tests
to detect the mean difference of hair counts across the
measurement time points by the repeated measures ana-
lysis of variance. Just like in the analysis of the age
groups, the tests were performed for each of the 4 skin
type groups, and once the results were found to be sig-
nificant, the post-hoc analysis of a linear trend, over time
was conducted. Between the complete dataset of 48 sub-
jects and the mixed dataset of 70 subjects, the results of
analysis were again largely consistent even though the
imputation captured the marginal significance of the
mean difference of hair counts over time for the skin
type III (p-value = 0.0346). The skin type I, had the least
number of subjects assigned in both cases, and it did not
show any significant mean difference of hair counts nor
a linear trend over time. Although not clear, it seems
that the least sensitive skin type responds the best to the
device for the hair growth over time. Again, low R2 values
indicated the presence of large variability which cannot be
accounted for by the duration of the device usage only.
Discussion
While this multi-centered study was originally planned
as a randomized –sham –controlled double-blinded clin-
ical study, it was determined following the investigation
as planned, that the sham device was emitting hair
growth light that ruined the control data and subsequent
results. However, the present results provide significant
impetus to develop a better sham device and design a
clinical study in a larger cohort.
With that stated, this pilot study to evaluate the effi-
cacy of the cold X5 hairlaser device for treating male
AGA resulted in a statistically significant positive trend,











Mixed data (n = 70) I 7 0.66
II 20 5.19
III 27 2.49
IV 16 4.73variance, it was shown that the difference in mean hair
counts over time is statistically significant (F = 7.70;
p-value < 0.0001). Subsequently, a linear regression on
the mean hair counts at each measurement time point
was performed as a post-hoc analysis, and it was found
that a systematically increasing trend of hair growth over
time is statistically significant (p-value < 0.0001) with the
estimated slope of 1.406. The increase in hair counts,
at the end points, from the baseline to the end of the
26-week period, was nevertheless, found to be strongly
significant (p-value = 0.0003). As stated earlier to con-
firm that this effect was caused by the device and not by
a random chance, a more systematic comparative study
should be conducted with an appropriate control.
The main limitation of this investigation is the inability
to show the difference between the device and an appro-
priate sham control. The investigation is also limited by
the size of the population studied. In future studies we
intend to increase our population since this is a non-
invasive procedure. However, we are encouraged that
because of the stringent inclusion/exclusion criteria these
potentially important results will be confirmed in neces-
sary larger –controlled clinical trials, in the future.
The short-term safety of the device was ensured since
during the 26 weeks of this study, no any clinically
severe adverse events were associated with the X5 hair-
laser device.
While we cannot detail the mechanism of action of
the X5 (see below) the device was designed to deliver
low level laser light directly to the scalp bypassing any
intervening hair. The light is delivered by light tines
(15 light pipes mounted on five tripods) so that the
device conforms to the contour of the scalp and makes
direct contact. Other devices simply direct beams into
the hair and scalp at angles that cannot be precisely
controlled.
Moreover, this low-level laser therapy is intended to
bio-stimulate. The effects are biochemical not thermal
because the low power nature of low-level laser’s, cannot
cause heating damage to living tissue. Lasers are of twoach skin type
ted measures ANOVA Post-hoc linear trend test
p-value p-value Slope R2 value
0.6897 – – –
0.0135 0.0464 1.400 0.0053
0.1879 – – –
0.0011 0.0003 2.114 0.0229
0.6599 – – –
0.0003 0.0006 1.791 0.0083
0.0346 0.0046 0.953 0.0025
0.0008 0.0004 1.846 0.0169
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guished by the amount of peak power they deliver. "Hot"
lasers deliver power up to thousands of watts. They are
used in surgery because they can make an incision that
is very clean with little or no bleeding and because the
laser cauterizes the incision as it cuts. They are also used
in surgery that requires the removal of unhealthy tissue
without damaging the healthy tissue that surrounds it.
"Cold" lasers such as the X5 HairLaser produce a
lower average power of 100 milliwatts or less. This is the
type of laser that is used for therapeutic purposes and it
is typically, although not always, pulsed. The light is on
for only a fraction of a second because it is pulsed,
(turned on and off ) at so many pulses per second. Pulsa-
tion results in an average power output that is very low
compared to the maximum or peak output. Therefore,
most therapeutic lasers produce a high peak but low
average power output. Therapeutic laser is low-level laser
therapy (LLLT) with photochemical rather than thermal
effects [25-28]. The light is either visible (red), in most
cases or invisible (infrared).Proposed mechanism of action
Energy is transferred in the form of photons [25]. Pho-
tons are transmitted through the skin's layers (the der-
mis, epidermis and the subcutaneous tissue or tissue fat
under the skin). Light waves in the near infrared ranges
penetrate deeper than all light waves in the visible
spectrum. Photons enter the tissue and are absorbed in
the mitochondria and at the cell membrane [26]. The
photon energy is converted to chemical energy within
the cell in the form of adenosine triphosphate (ATP)
[27]. Light emitting diode (LED) in the red region and
low-level laser in the near infrared region correspond
well with the characteristic energy and absorption levels
of the relevant components of the respiratory chain. This
LED and Laser stimulation vitalizes the cell by increas-
ing the mitochondrial ATP production [28].
It is believed that successful laser therapy treatment
starts with the stimulation of cell functions by the laser
light. Research has shown that mitochondria are sensi-
tive to irradiation with monochromatic light [29]. Irradi-
ation with light at a wavelength of 650 nm enhances
ATP synthesis [28]. The increase in ATP is believed to
be one of the underlying mechanisms that help to stimu-
late hair follicles [30].
Although it is difficult to ascribe an accurate mechan-
ism of action of the “Cold” X5L, the hypothesis, that
irradiation of the scalp with this hair laser device will
result in a statistically significant increase in hair growth
as compared to a control, is supported by the combin-
ation of mechanisms that increase both ATP production
and microcirculation.Conclusions
While there are number of drugs and even other tech-
niques to induce hair follicle growth alternatives are still
important [31-33]. Albeit, sham device failure and result-
ant missing data from the control group, the positive
trend hair growth due to the chronic use of X5hairlaser
device was observed. This potential positive benefit is in
full agreement with other low laser hair devices and
following required larger confirmatory studies should
have clinical utility for treating male AGA.
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